India Thalassemia Market is predicted to reach USD 0.38 billion at a CAGR of 5.03% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global India Thalassemia Market”.

The India thalassemia market is projected to register a CAGR of 5.03% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the India thalassemia market are Novartis AG (Switzerland), Cipla, Inc. (India), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb (US), Agios Pharmaceuticals, Inc. (US), Centurion Remedies Private Limited. (India), Healing Pharma India Pvt. Ltd. (India), Rewine Pharmaceuticals (India), Cadila Pharmaceuticals (India), and Trexgen Pharmaceuticals Pvt Ltd. (India).

Market Highlights

The India thalassemia market is accounted to register a CAGR of 5.03% during the forecast period and is estimated to reach USD 0.38 billion by 2032.

Thalassemia treatment program for medicine focuses on managing the symptoms and complications of this genetic blood disorder. The primary goal of treatment is to maintain an adequate level of hemoglobin in the body to prevent severe anemia and related complications. Regular blood transfusions are a common part of the treatment regimen for thalassemia patients. These transfusions provide healthy red blood cells and help increase the oxygen-carrying capacity of the blood. However, frequent transfusions also lead to iron overload in the body, requiring the administration of iron chelation drug to remove excess iron. For the same reason, there are several programs that assist thalassemia patients financially. For instance, in May 2023, COAL INDIA Launched Thalassemia Bal Sewa Yojana (TBSY)—Phase III—on World Thalassemia Day 2023 with an outlay of USD 300 million. The program has extended financial assistance of up to USD 0.012 million to each patient fitting the scheme criteria for the treatment including therapies. Although state governments are responsible for providing free treatment for Thalassemia, the National Health Mission (NHM) offers additional support. This support also includes funding for iron chelation drugs and states need to submit annual proposals to the NHM outlining their plans for utilizing this support. Thus, the increasing financial support boosts the growth of the market and also develops confidence in patients to continue their treatment.

Additionally, advancements in prenatal and newborn screening technologies have revolutionized the detection and management of thalassemia. These technologies allow for the early identification of thalassemia carriers and affected individuals, enabling physicians to provide timely interventions and treatments. There are manufacturers in India that are actively developing newborn and prenatal screening technologies and also launching non-invasive prenatal testing (NIPT) services. For instance, in March 2021, Bioserve Biotechnologies Pvt. Ltd. (India), a wholly owned subsidiary of REPROCELL, Inc. (US), launched non-invasive prenatal testing (NIPT) services in India. Bioserve offers advanced preimplantation genetic screening and diagnosis (PGS/PGD), diagnostic testing for prenatal and postnatal cases, and carrier screening services under the PRENITA brand, in addition to the launch of NIPT. Therefore, the above-mentioned market drivers are boosting the growth of the India thalassemia market.

Access full report @ https://www.marketresearchfuture.com/reports/india-thalassemia-market-22054

Segment Analysis

The India thalassemia market has been segmented based type and treatment & diagnosis.

Based on type, the India thalassemia market is segmented into alpha-thalassemia and beta-thalassemia. Beta-thalassemia held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2032. Factors driving the growth of the type segment are rising awareness about genetic screening and prenatal diagnosis, rising prevalence of alpha-thalassemia in certain populations, and increasing collaborations between pharmaceutical companies and research institutions.

On the basis of treatment & diagnosis, the India thalassemia market is segmented into treatment and diagnosis. The treatment segment further divided into blood transfusions, drugs, and folic acid supplements immunoassay and diagnosis is bifurcated into instruments and reagents. Treatment held the largest market share in 2022 and diagnosis is anticipated to register the highest CAGR from 2022 to 2032. The drivers that are boosting the growth of the treatment & diagnosis segment are growing research and development for novel drug therapies, increasing awareness about the importance of folic acid supplementation in thalassemia, growing emphasis on micronutrient, and government initiatives and support.

Key Findings of the Study

• The India thalassemia market is expected to reach USD 0.38 billion by 2032, at a CAGR of 5.03% during the forecast period.


• Based on type, the beta-thalassemia segment held the largest market with a market share of 33% in 2022 and is the fastest-growing segment during the forecast period.


• Novartis AG (Switzerland), Cipla, Inc. (India), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb (US), Agios Pharmaceuticals, Inc. (US), Centurion Remedies Private Limited. (India), Healing Pharma India Pvt. Ltd. (India), Rewine Pharmaceuticals (India), Cadila Pharmaceuticals (India), and Trexgen Pharmaceuticals Pvt Ltd. (India) are the key players in the market.